Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)
File version
Author(s)
Barone, D
Broadley, S
Dive, D
Hupperts, RMM
Lycke, J
Massacesi, L
Montalban, X
Naismith, RT
Pandey, K
Schippling, S
Vermersch, P
Chung, L
Daizadeh, N
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Berlin, Germany
License
Abstract
Aims: Evaluate efficacy and safety of alemtuzumab over 6 y in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I.
Methods: At investigator discretion, patients in TOPAZ can receive additional as-needed alemtuzumab (≥12 months apart; no criteria), or receive another DMT (at any time). MRI disease activity was defined as new gadolinium (Gd)-enhancing or new/enlarging T2 hyperintense lesions.
Results: Of 139 patients initiating alemtuzumab in the extension, 117 (84%) completed Y2 of TOPAZ (Y6 after initiating alemtuzumab); 67% received neither additional courses of alemtuzumab nor another DMT. At Y6, the annualised relapse rate was 0.19, and 70% of patients had stable/improved EDSS scores from CARE-MS I baseline. After initiating alemtuzumab, 69% were free from 6-month confirmed disability worsening and 28% had 6-month confirmed disability improvement. At Y6, 62% were free of MRI disease activity, 82% were free of new Gd-enhancing lesions, and 62% were free of new/enlarging T2 hyperintense lesions. Median percent cumulative brain volume loss (BVL) from CARE-MS I baseline was -1.99% over 8 total study y; -1.49% occurred over Y0-2 with SC IFNB-1a, and -0.23% occurred over 6 y with alemtuzumab. Safety was consistent with the alemtuzumab arm of the core and extension studies.
Conclusions: Alemtuzumab improved clinical, MRI, and BVL outcomes in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. These improved outcomes were maintained over 6 y in the absence of continuous treatment, with a consistent safety profile that is manageable and acceptable.
Journal Title
Conference Title
Multiple Sclerosis Journal
Book Title
Edition
Volume
24
Issue
Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Neurosciences
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
Persistent link to this record
Citation
Van Wijmeersch, B; Barone, D; Broadley, S; Dive, D; Hupperts, RMM; Lycke, J; Massacesi, L; Montalban, X; Naismith, RT; Pandey, K; Schippling, S; Vermersch, P; Chung, L; Daizadeh, N; et al., Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study), Multiple Sclerosis Journal, 2018, 24, pp. 488-489